샘플 요청 목록

 카트 문의
시장보고서
상품코드
1766893

세계의 진통제 시장

Analgesics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 578 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

진통제 세계 시장은 2030년까지 728억 달러에 달할 전망

2024년에 535억 달러로 추정되는 진통제 세계 시장은 2024년부터 2030년까지 CAGR 5.3%로 성장하여 2030년에는 728억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 처방약은 CAGR 5.0%를 기록하며 분석 기간 종료시에는 438억 달러에 달할 것으로 예측됩니다. OTC 부문의 성장률은 분석 기간 동안 CAGR 5.8%로 추정됩니다.

미국 시장은 172억 달러로 추정, 중국은 CAGR 7.1%로 성장 예측

미국의 진통제 시장은 2024년에 172억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 108억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 7.1%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.8%와 4.2%로 예측됩니다. 유럽에서는 독일이 CAGR 4.1%로 성장할 것으로 예측됩니다.

세계의 진통제 시장 동향과 촉진요인 정리

일반적으로 진통제로 알려진 진통제는 통증을 완화하기 위해 사용되는 다양한 약물군입니다. 진통제는 뇌의 통증 신호를 차단하거나 뇌가 이 신호를 해석하는 것을 방해함으로써 효과를 발휘합니다. 진통제는 여러 종류가 있으며, 각각 통증의 종류와 정도에 따라 적합한 진통제가 있습니다. 가장 잘 알려진 것은 이부프로펜이나 아스피린과 같은 비스테로이드성 항염증제(NSAIDs)로, 염증을 억제하고 경증에서 중등도의 통증에 효과적입니다. 모르핀이나 옥시코돈과 같은 오피오이드는 더 강한 진통제로서 심한 통증에 처방되는 경우가 많지만, 의존성이나 중독의 위험이 있습니다. 또 다른 범주는 아세트아미노펜(파라세타몰)으로, 경증에서 중등도의 진통과 해열에 널리 사용되며 일반의약품에도 많이 포함되어 있습니다.

진통제의 사용은 의학 연구의 발전과 통증의 메커니즘에 대한 이해가 깊어짐에 따라 해마다 크게 발전하고 있습니다. 서방형 정제, 경피흡수 패치와 같은 새로운 제형과 투여 방법으로 통증 관리의 효과와 편의성이 향상되었습니다. 또한, 한 번의 투여로 여러 진통제를 통합한 복합제의 개발로 서로 다른 통증 경로를 동시에 표적화하여 통증 완화 효과를 향상시켰습니다. 그러나 오피오이드를 중심으로 한 진통제의 광범위한 사용은 높은 중독 및 과다복용률을 특징으로 하는 오피오이드 위기 등 심각한 공중보건 문제를 야기하고 있습니다. 이에 따라 위장 부작용이 적은 새로운 비스테로이드성 항염증제 개발, 비약물 요법 연구 활성화 등 보다 안전하고 의존성이 없는 진통 방법을 찾는 방향으로 전환되고 있습니다.

진통제 시장의 성장은 여러 가지 요인에 의해 주도되고 있습니다. 약물전달 시스템의 발전으로 진통제가 보다 효과적이고 사용자 친화적인 진통제를 만들 수 있게 되었고, 환자 제어형 진통제 펌프와 웨어러블 약물전달 기기와 같은 혁신이 인기를 얻고 있습니다. 관절염, 암 등 장기적인 통증 관리가 필요한 만성질환의 유병률 증가도 진통제에 대한 수요를 촉진하고 있습니다. 또한, 고령화 사회로 접어들면서 노인들이 만성 통증 질환을 겪을 가능성이 높아짐에 따라 진통제 소비가 증가하고 있습니다. 소비자 행동 트렌드에서는 빠른 통증 완화를 위해 시판되는 진통제를 선호하는 경향이 강화되고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다. 또한, 신흥국 시장의 의료비 지출 증가와 의료 접근성 향상으로 시장 저변이 확대되고 있습니다. 제약사들도 기존 진통제를 대체할 수 있는 안전한 진통제에 대한 수요 증가에 대응하여 보다 우수한 안전성과 효능을 가진 새로운 진통제를 개발하기 위해 연구개발에 많은 투자를 하고 있습니다. 이러한 요인들이 진통제 시장의 역동적이고 확장적인 특성을 뒷받침하고 있습니다.

부문

약물 유형(처방약, OTC), 약물 종류(오피오이드, NSAIDs, 기타 약물 종류), 투여 경로(경구, 비경구, 국소, 경피, 직장)

조사 대상 기업 사례

  • Bristol-Myers Squibb Company
  • Bayer AG
  • Biological E. Ltd.
  • Anabolic Laboratories LLC
  • BioDelivery Sciences International, Inc.
  • Brawn Laboratories Ltd.
  • Angelini Holding S.p.A.
  • AFT Pharmaceuticals Limited
  • APT Asia Pacific
  • Church & Dwight(Australia) Pty Ltd.
  • Alliance Design and Development Group, Inc.
  • Active Releaf Wellness Inc.
  • Abiogen Pharma S.p.A.
  • B-New Limited
  • Celgene Corporation

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범에 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망
  • 세계의 브랜드

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.07.16

Global Analgesics Market to Reach US$72.8 Billion by 2030

The global market for Analgesics estimated at US$53.5 Billion in the year 2024, is expected to reach US$72.8 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Prescription, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$43.8 Billion by the end of the analysis period. Growth in the OTC segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$17.2 Billion While China is Forecast to Grow at 7.1% CAGR

The Analgesics market in the U.S. is estimated at US$17.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.8 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Analgesics Market - Key Trends & Drivers Summarized

Analgesics, commonly known as painkillers, are a diverse group of drugs used to relieve pain. They work by blocking pain signals in the brain or by interfering with the brain's interpretation of these signals. There are several types of analgesics, each suited to different types and severities of pain. The most well-known categories include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin, which reduce inflammation and are effective for mild to moderate pain. Opioids like morphine and oxycodone are stronger analgesics, often prescribed for severe pain but come with a risk of dependency and addiction. Another category is acetaminophen (paracetamol), which is widely used for mild to moderate pain relief and fever reduction, often included in over-the-counter medications.

The use of analgesics has evolved significantly over the years, driven by advances in medical research and an increasing understanding of pain mechanisms. New formulations and delivery methods, such as extended-release tablets and transdermal patches, have improved the efficacy and convenience of pain management. Additionally, the development of combination drugs that incorporate multiple analgesics into a single dose has enhanced pain relief outcomes by targeting different pain pathways simultaneously. However, the widespread use of analgesics, particularly opioids, has led to significant public health challenges, including the opioid crisis, characterized by high rates of addiction and overdose. This has prompted a shift towards finding safer, non-addictive pain relief options, such as the development of new NSAIDs with fewer gastrointestinal side effects and increased research into non-pharmacological therapies.

The growth in the analgesics market is driven by several factors. Advancements in drug delivery systems have made analgesics more effective and user-friendly, with innovations like patient-controlled analgesia pumps and wearable drug delivery devices gaining popularity. The rising prevalence of chronic diseases such as arthritis and cancer, which often require long-term pain management, has also fueled demand for analgesics. Additionally, an aging global population is contributing to increased consumption of these medications, as older adults are more likely to experience chronic pain conditions. Consumer behavior trends show a growing preference for over-the-counter analgesics for quick and accessible pain relief, further boosting market growth. Moreover, increased healthcare spending and greater access to medical care in developing regions are expanding the market's reach. Pharmaceutical companies are also investing heavily in research and development to create new analgesics with better safety profiles and effectiveness, responding to the growing demand for safer alternatives to traditional painkillers. These factors collectively underscore the dynamic and expanding nature of the analgesics market.

SCOPE OF STUDY:

The report analyzes the Analgesics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Prescription, OTC); Drug Class (Opioids, NSAIDs, Other Drug Classes); Route of Administration (Oral, Parenteral, Topical, Transdermal, Rectal)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 146 Featured) -

  • Bristol-Myers Squibb Company
  • Bayer AG
  • Biological E. Ltd.
  • Anabolic Laboratories LLC
  • BioDelivery Sciences International, Inc.
  • Brawn Laboratories Ltd.
  • Angelini Holding S.p.A.
  • AFT Pharmaceuticals Limited
  • APT Asia Pacific
  • Church & Dwight (Australia) Pty Ltd.
  • Alliance Design and Development Group, Inc.
  • Active Releaf Wellness Inc.
  • Abiogen Pharma S.p.A.
  • B-New Limited
  • Celgene Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Analgesics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • A Prelude to Analgesics
    • Analgesics: Perfect Therapeutic Options to Solve Mild to Crippling Pain
    • Key Segments
    • Opioid Analgesics
    • Non-Opioid Analgesics
    • NSAIDs
    • Topical NSAIDs
    • Others
    • Acetaminophen
    • Adjuvant Analgesics
    • Global Analgesics Market to Witness Rapid Growth
    • Drugs Indicated for Pain Management
    • The US and Europe Represent the Largest Regions, Asia-Pacific to Witness fastest Growth
    • Non-Opioids: Fastest Growing Category
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Aging Population & Increasing Burden of Chronic Diseases Spurs
    • Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • Rising Diabetes Prevalence Presents Opportunity for Cell Surface Markers: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
    • Growing Incidence of Cancer and the Associated Pain to Drive the Analgesics Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Advancements in Design and Delivery of Analgesic Drugs
    • Development of Safer Opioids with More Safer Profiles
    • Drug Pipeline with Efficacious Drugs
    • OTC Analgesics Market to Witness Fastest Growth
    • Topical Analgesics Market Holds Significant Share
    • Combination Therapies Gain Prominence
    • A Few Novel Analgesic Products under Development
    • E-commerce Platforms Strengthen Pharmaceutical Distribution in Crisis Period
    • Neuropathic Pain Management: Market with High Potential
    • Migraine Market: A Core Vertical in CNS Pain Management
    • Reyvow, Eli Lilly's Novel Migraine Drug with the Potential to Lead the Global Migraine Medications Market
    • Three New Migraine Drugs Obtain FDA Approval
    • Eli Lilly's Emgality Receives FDA Approval
    • Increasing Cases of Peripheral Nerve Injuries Drive the Analgesics Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Prescription by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Prescription by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for OTC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for OTC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Rectal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Rectal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Analgesics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • WORLD BRANDS

III. MARKET ANALYSIS

  • UNITED STATES
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • JAPAN
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • CHINA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • EUROPE
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Analgesics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • GERMANY
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Analgesics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • INDIA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Analgesics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Analgesics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030
  • AFRICA
    • Analgesics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Analgesics by Drug Type - Prescription and OTC - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Analgesics by Drug Type - Prescription and OTC Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Analgesics by Drug Type - Percentage Breakdown of Value Sales for Prescription and OTC for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Analgesics by Drug Class - Opioids, NSAIDs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Analgesics by Drug Class - Percentage Breakdown of Value Sales for Opioids, NSAIDs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Analgesics by Route Of Administration - Oral, Parenteral, Topical, Transdermal and Rectal Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Analgesics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Parenteral, Topical, Transdermal and Rectal for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제